Vanguard Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$4.95B Buy
9,424,048
+16,157
+0.2% +$8.48M 0.08% 246
2025
Q1
$5.97B Buy
9,407,891
+121,545
+1% +$77.1M 0.11% 165
2024
Q4
$6.61B Sell
9,286,346
-33,944
-0.4% -$24.2M 0.12% 149
2024
Q3
$9.8B Buy
9,320,290
+326,320
+4% +$343M 0.18% 96
2024
Q2
$9.45B Buy
8,993,970
+63,729
+0.7% +$67M 0.18% 95
2024
Q1
$8.6B Buy
8,930,241
+91,956
+1% +$88.5M 0.17% 103
2023
Q4
$7.76B Buy
8,838,285
+39,780
+0.5% +$34.9M 0.17% 104
2023
Q3
$7.24B Sell
8,798,505
-58,533
-0.7% -$48.2M 0.18% 96
2023
Q2
$6.36B Buy
8,857,038
+4,917
+0.1% +$3.53M 0.15% 109
2023
Q1
$7.27B Buy
8,852,121
+129,673
+1% +$107M 0.19% 95
2022
Q4
$6.29B Buy
8,722,448
+74,323
+0.9% +$53.6M 0.17% 110
2022
Q3
$5.96B Buy
8,648,125
+77,380
+0.9% +$53.3M 0.18% 100
2022
Q2
$5.07B Buy
8,570,745
+210,415
+3% +$124M 0.14% 124
2022
Q1
$5.84B Buy
8,360,330
+201,815
+2% +$141M 0.14% 122
2021
Q4
$5.15B Buy
8,158,515
+87,234
+1% +$55.1M 0.12% 152
2021
Q3
$4.88B Buy
8,071,281
+101,621
+1% +$61.5M 0.12% 144
2021
Q2
$4.45B Sell
7,969,660
-30,752
-0.4% -$17.2M 0.11% 158
2021
Q1
$3.79B Buy
8,000,412
+69,192
+0.9% +$32.7M 0.1% 174
2020
Q4
$3.83B Sell
7,931,220
-57,008
-0.7% -$27.5M 0.11% 160
2020
Q3
$4.47B Buy
7,988,228
+143,233
+2% +$80.2M 0.15% 117
2020
Q2
$4.89B Buy
7,844,995
+1,429,765
+22% +$892M 0.17% 99
2020
Q1
$3.13B Buy
6,415,230
+162,927
+3% +$79.6M 0.13% 143
2019
Q4
$2.35B Buy
6,252,303
+47,835
+0.8% +$18M 0.08% 261
2019
Q3
$1.72B Buy
6,204,468
+125,121
+2% +$34.7M 0.06% 338
2019
Q2
$1.9B Buy
6,079,347
+54,247
+0.9% +$17M 0.07% 295
2019
Q1
$2.47B Buy
6,025,100
+127,067
+2% +$52.2M 0.1% 203
2018
Q4
$2.2B Buy
5,898,033
+143,106
+2% +$53.5M 0.1% 195
2018
Q3
$2.33B Buy
5,754,927
+75,868
+1% +$30.7M 0.09% 213
2018
Q2
$1.96B Buy
5,679,059
+71,435
+1% +$24.6M 0.08% 246
2018
Q1
$1.93B Buy
5,607,624
+113,573
+2% +$39.1M 0.08% 241
2017
Q4
$2.07B Buy
5,494,051
+94,540
+2% +$35.5M 0.09% 233
2017
Q3
$2.41B Buy
5,399,511
+129,053
+2% +$57.7M 0.11% 179
2017
Q2
$2.59B Buy
5,270,458
+148,962
+3% +$73.2M 0.13% 150
2017
Q1
$1.98B Buy
5,121,496
+199,975
+4% +$77.5M 0.1% 197
2016
Q4
$1.81B Buy
4,921,521
+110,090
+2% +$40.4M 0.1% 208
2016
Q3
$1.93B Buy
4,811,431
+32,245
+0.7% +$13M 0.11% 178
2016
Q2
$1.67B Buy
4,779,186
+92,467
+2% +$32.3M 0.1% 205
2016
Q1
$1.69B Buy
4,686,719
+129,032
+3% +$46.5M 0.11% 186
2015
Q4
$2.47B Buy
4,557,687
+131,565
+3% +$71.4M 0.17% 116
2015
Q3
$2.06B Buy
4,426,122
+130,937
+3% +$60.9M 0.15% 126
2015
Q2
$2.19B Buy
4,295,185
+108,784
+3% +$55.5M 0.15% 129
2015
Q1
$1.89B Buy
4,186,401
+175,718
+4% +$79.3M 0.13% 158
2014
Q4
$1.65B Buy
4,010,683
+151,130
+4% +$62M 0.12% 167
2014
Q3
$1.39B Sell
3,859,553
-54,150
-1% -$19.5M 0.11% 182
2014
Q2
$1.11B Sell
3,913,703
-1,186
-0% -$335K 0.09% 241
2014
Q1
$1.18B Buy
3,914,889
+129,159
+3% +$38.8M 0.1% 212
2013
Q4
$1.04B Buy
3,785,730
+91,460
+2% +$25.2M 0.09% 229
2013
Q3
$1.16B Sell
3,694,270
-583,340
-14% -$183M 0.11% 172
2013
Q2
$962M Buy
+4,277,610
New +$962M 0.1% 197